Michael Witcher
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Michael Witcher is an Associate Professor at The Lady Davis Institute of the Jewish General Hospital, McGill University, Canada. His research primarily focuses on the modulation of mTOR pathways, chromatin remodeling, and the oncogenic functions of CTCF mutations, particularly in the context of cancer biology. Recent publications highlight his contributions to understanding the mechanisms of cancer treatment, including the use of BET inhibitors and the response of triple-negative breast cancers to PARP inhibitors.
Articles (7)
While most individuals with familial medullary thyroid carcinoma (fMTC) carry RET mutations, in some instances the causative mutations remain unknown. We studied two related families with RET-negative fMTC in 21 affected individuals through linkage analysis, exome/genome sequencing, and high-density array comparative genomic hybridization. We identified a novel heterozygous 40kb intragenic SLC30A9 deletion which segregated with the disease in all affected individuals. The mutant transcript escaped nonsense-mediated decay and resulted in the production of N-terminally truncated proteins via translation reinitiation from in-frame AUG codons located downstream of the deletion. These proteins showed increased stability and their expression in an MTC cell line increased cell proliferation and clonogenic capacity, supporting an oncogenic role. These findings expand the genetic background of fMTC beyond RET mutations and implicate translation reinitiation in the etiology of cancer susceptibility syndromes secondary to structural genomic variants.
Year:
2026
Year:
2024
The pogo transposable element–derived zinc finger protein, POGZ, is notably associated with neurodevelopmental disorders through its role in gene transcription. Many proteins involved in neurological development are often dysregulated in cancer, suggesting a potential role for POGZ in tumor biology. Here, we provided experimental evidence that POGZ influences the growth and metastatic spread of triple-negative breast cancers (TNBC). In well-characterized models of TNBC, POGZ exerted a dual role, both as a tumor promoter and metastasis suppressor. Mechanistically, loss of POGZ potentiated TGFβ pathway activation to exert cytostatic effects while simultaneously increasing the mesenchymal and migratory properties of breast tumors. Although POGZ levels are elevated in human breast cancers, the most aggressive forms of TNBC tumors, including those with increased mesenchymal and metastatic properties, exhibit dampened POGZ levels, and low POGZ expression was associated with inferior clinical outcomes in these tumor types. Taken together, these data suggest that POGZ is a critical suppressor of the early stages of the metastatic cascade. Significance: The POGZ neurodevelopmental protein plays dual functions in triple-negative breast cancers as a tumor promoter and metastasis suppressor, inhibiting TGFβ-regulated EMT to limit breast cancer metastatic progression.
Year:
2024
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Collaborators (19)
Alexandre Orthwein
Assistant Professor
Emory University School of Medicine
Federica Begalli
Lecturer in Endocrinology
Queen Mary University of London
William Foulkes
Full Professor
McGill University
Marton Doleschall
senior scientist
Semmelweis University
Horia Constantin Stanescu
University College London
Maralyn Druce
-
Jolanta Krajewska
Associate Professor
Maria Sklodowska-Curie Institute - Oncology Center Gliwice Branch
Anne Barlier
Aix-Marseille University
Maria Alevizaki
Professor of Endocrinology
National and Kapodistrian University of Athens
Sabrina Chiloiro
Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia
Márta Korbonits
Deputy Director of the William Harvey Research Institute
Queen Mary University of London
Donato Iacovazzo
NIHR Clinical Lecturer
Queen Mary University of London
Malgorzata Oczko-Wojciechowska
Head of Department/Ph.D
Maria Sklodowska-Curie National Research Institute of Oncology
Jes Mathiesen
University of Southern Denmark
Claudia Kleinman
Professor
McGill University
R Mihai
Oxford University Hospitals NHS Foundation Trust
Suvi Savola
Head of Oncogenetics
MRC-Holland
James R. Lupski
-
Miklós Tóth
professor
Semmelweis University
Make your next move.
Prepare your application
Review drafts before you send them.